Franklin Huang, MD, PhD

Assistant Professor
Research Description: 

Dr. Franklin Huang is a physician-scientist and medical oncologist who cares for patients with prostate cancer.

Huang's lab examines genetic differences between cancer cells and normal tissue, aiming to determine what makes certain tumors more aggressive. His work seeks to understand prostate cancer in African Americans and to develop better treatments. His other areas of study include finding new drug targets for cancer patients with precision medicine (an approach that individualizes treatment by considering factors such as genetics and environment) and global oncology (a field focused on expanding access to cancer prevention and treatment). His research receives support from the National Institutes of Health, the United States Department of Defense, the Prostate Cancer Foundation, the Benioff Initiative for Prostate Cancer Research, the Chan Zuckerberg Biohub San Francisco, and the Chan Zuckerberg Initiative.

Huang earned his doctorate in genetics from Harvard Medical School and his medical degree from Washington University School of Medicine in St. Louis. He completed a residency in internal medicine at Massachusetts General Hospital and a fellowship in hematology and oncology at Dana-Farber Cancer Institute; both hospitals are Harvard affiliates. He is a co-founder of Global Oncology, a nonprofit working to improve cancer care for underserved patients around the world.

Primary Thematic Area: 
Cancer Biology & Cell Signaling
Secondary Thematic Area: 
Human Genetics
Research Summary: 
Our lab uses cancer genomics to study the molecular mechanisms of carcinogenesis, cancer disparities, and cellular immortality.

Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer.

Cancer immunology research

Choudhury AD, Kwak L, Cheung A, Allaire KM, Marquez J, Yang DD, Tripathi A, Kilar JM, Flynn M, Maynard B, Reichel R, Pace AF, Chen BK, Van Allen EM, Kilbridge K, Wei XX, McGregor BA, Pomerantz MM, Bhatt RS, Sweeney CJ, Bubley GJ, Jacene HA, Taplin ME, Huang FW, Harshman LC, Fong L

RPL22 is a tumor suppressor in MSI-high cancers and a key splicing regulator of MDM4.

bioRxiv : the preprint server for biology

Weinstein HNW, Hu K, Fish L, Chen YA, Allegakoen P, Hui KSF, Pham JH, Baco MB, Song H, Giacomelli AO, Vazquez F, Ghandi M, Goodarzi H, Huang FW

Single-nuclei characterization of pervasive transcriptional signatures across organs in response to COVID-19.


COVID Tissue Atlas Consortium, Granados AA, Bucher S, Song H, Agrawal A, Chen AT, Peng T, Neff N, Pisco AO, Huang F, Wang B

Racial disparity in the genomics of precision oncology of prostate cancer.

Cancer reports (Hoboken, N.J.)

Le T, Rojas PS, Fakunle M, Huang FW

Club-like cells in proliferative inflammatory atrophy of the prostate.

The Journal of pathology

Huang FW, Song H, Weinstein HN, Xie J, Cooperberg MR, Hicks J, Mummert L, De Marzo AM, Sfanos KS